{"id":10250,"date":"2020-06-29T09:36:52","date_gmt":"2020-06-29T09:36:52","guid":{"rendered":"https:\/\/bgrssb.icgbio.ru\/2020\/2020\/06\/29\/catalytically-active-bispecific-antibodies-new-biochemical-markers-of-hiv-aids\/"},"modified":"2020-06-29T09:36:52","modified_gmt":"2020-06-29T09:36:52","slug":"catalytically-active-bispecific-antibodies-new-biochemical-markers-of-hiv-aids","status":"publish","type":"post","link":"https:\/\/bgrssb.icgbio.ru\/2020\/2020\/06\/29\/catalytically-active-bispecific-antibodies-new-biochemical-markers-of-hiv-aids\/","title":{"rendered":"Catalytically active bispecific antibodies – new biochemical markers of HIV\/AIDS"},"content":{"rendered":"

Svetlana Baranova1<\/sup>, Sergey Sedykh2<\/sup>, Georgy Nevinsky3<\/sup>
1<\/sup>SB RAS ICBFM, swb@niboch.nsc.ru
2<\/sup>SB RAS ICBFM, NSU, sedyh@niboch.nsc.ru
3<\/sup>SB RAS ICBFM, NSU, nevinsky@niboch.nsc.ru<\/p>\n

HIV-infection is a viral disease, causing an immune deficiency. In patients with HIV\/AIDS there were described a number of changes similar to autoimmune processes.\u0412\u00a0An important problem of HIV\/AIDS research is the prognosis of infection. As it was previously shown, autoimmune processes damage the nervous systems, and one of the markers of these processes are catalytic antibodies and bispecific antibodies. Such antibodies in vitro<\/em>\u0412\u00a0can hydrolyze neurospecific substrates.<\/p>\n

Similiar antibodies were described in the blood of healthy donors, patients with systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Proteolytic IgGs hydrolyze myelin basic protein and oligodendrocytic peptide. We have shown that sera of HIV\/AIDS, SLE and MS patients contain autoantibodies against histones and myelin basic protein.<\/p>\n

Here we show the results of research of natural bispecific catalytically active antibodies isolated from the blood of HIV\/AIDS patients. Also, we compared the level of the protease activity of antibodies with the stage and characteristics of the pathological process. Interestingly, the pathological processes in HIV\/AIDS are similar with such in MS and SLE. The development of new methods for diagnosing the patient\u0432\u0402\u2122s condition, the effectiveness of therapy, and also predicting disease outcome in the future can be used for personalized therapy and improving the patient\u0432\u0402\u2122s quality of life.<\/p>\n

The research was supported by Grant of RFBR \u0432\u201e\u2013 20-34-70115.<\/p>\n","protected":false},"excerpt":{"rendered":"

Svetlana Baranova1, Sergey Sedykh2, Georgy Nevinsky31SB RAS ICBFM, swb@niboch.nsc.ru2SB RAS ICBFM, NSU, sedyh@niboch.nsc.ru3SB RAS ICBFM, NSU, nevinsky@niboch.nsc.ru HIV-infection is a viral disease, causing an immune deficiency. In patients with HIV\/AIDS there were described a number of changes similar to autoimmune processes.\u0412\u00a0An important problem of HIV\/AIDS research is the prognosis of infection. As it was previously shown, autoimmune processes damage the nervous systems, and one of the markers of these processes are catalytic antibodies and bispecific antibodies. Such antibodies in vitro\u0412\u00a0can hydrolyze neurospecific substrates. Similiar antibodies were described in the blood of healthy donors, patients with systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Proteolytic IgGs hydrolyze myelin basic protein and oligodendrocytic peptide. We have shown that sera of HIV\/AIDS, SLE and MS patients contain autoantibodies against histones and myelin basic protein. Here we show the results of research of natural bispecific catalytically active antibodies isolated from the blood of HIV\/AIDS patients. Also, we compared the level of the protease activity of antibodies with the stage and characteristics of the pathological process. Interestingly, the pathological processes in HIV\/AIDS are similar with such in MS and SLE. The development of new methods for diagnosing the patient\u0432\u0402\u2122s condition, the effectiveness of therapy, and also predicting disease outcome in the future can be used for personalized therapy and improving the patient\u0432\u0402\u2122s quality of life. The research was supported by Grant of RFBR \u0432\u201e\u2013 20-34-70115.<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2167],"tags":[1889,2021,2023,2022,2020],"_links":{"self":[{"href":"https:\/\/bgrssb.icgbio.ru\/2020\/wp-json\/wp\/v2\/posts\/10250"}],"collection":[{"href":"https:\/\/bgrssb.icgbio.ru\/2020\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bgrssb.icgbio.ru\/2020\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bgrssb.icgbio.ru\/2020\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/bgrssb.icgbio.ru\/2020\/wp-json\/wp\/v2\/comments?post=10250"}],"version-history":[{"count":0,"href":"https:\/\/bgrssb.icgbio.ru\/2020\/wp-json\/wp\/v2\/posts\/10250\/revisions"}],"wp:attachment":[{"href":"https:\/\/bgrssb.icgbio.ru\/2020\/wp-json\/wp\/v2\/media?parent=10250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bgrssb.icgbio.ru\/2020\/wp-json\/wp\/v2\/categories?post=10250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bgrssb.icgbio.ru\/2020\/wp-json\/wp\/v2\/tags?post=10250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}